Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 39 Ovarian Neoplasms 32 Triple Negative Breast Neoplasms 19 Prostatic Neoplasms 17 Fallopian Tube Neoplasms 16 Neoplasm Metastasis 14 Pancreatic Neoplasms 9 Neoplasms 9 Endometrial Neoplasms 9 Carcinoma, Non-Small-Cell Lung 7 Small Cell Lung Carcinoma 6 Parkinson Disease 4, Autosomal Dominant Lewy Body 6 Glioma 6 Stomach Neoplasms 5 Sarcoma 5 Lung Neoplasms 5 Glioblastoma 5 Squamous Cell Carcinoma of Head and Neck 4 Metastatic Castration-resistant Prostate Cancer 4 Carcinoma, Ovarian Epithelial 4 Solid Tumors 3 Recurrence 3 Osteosarcoma 3 Neuroendocrine Tumors 3 Lymphoma, Non-Hodgkin 3 Cholangiocarcinoma 3 Urinary Bladder Neoplasms 2 Sarcoma, Ewing 2 Rhabdomyosarcoma 2 Prostatic Neoplasms, Castration-Resistant 2

Interventions

Etoposide 2 pembrolizumab 1 olaparib 1 niraparib 1 atezolizumab 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

SCLC,Extensive Stage × olaparib × 1 year × Clear all

NCT05623319 2025-06-24

THOR

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Recruiting

SCLC,Extensive Stage

Data powered by HemOnc (CC BY 4.0) Colophon ⚡